Monoamine oxidase A (MAOA) is an enzyme involved in the metabolism of the monoamines, eg 5-HT and noradrenaline. It converts the monoamines into their corresponding carboxylic acid via an aldehyde intermediate. MAOA regulates both the free intraneuronal concentration and the releasable stores of 5-HT and noradrenaline. MAOA inhibitors bind to and inhibit MAOA, preventing monoamine degradation. This results in greater stores of monoamines available for release. MAOA inhibitors are used in the treatment of depression. It has been proposed that MAO inhibitors treat depression by preventing monoamine degrdation and delaying downregulation of beta-andrenoceptors and 5-HT2 receptors.

Click here: Discover the role of MAO-A inhibitors in depression treatment

file_download Download in HQ

Related content

image Image
Parkinson’s Disease and Braak stages

The Braak staging scheme is a valuable model for conceptualizing PD progression and categorizes PD into stages of neuropathological changes.

11.04.2024 Parkinson’s Disease
Unmet Medical Needs in Bipolar Disorder and The Role of Clinicians in Addressing Them play_circle Video play_circle
Unmet Medical Needs in Bipolar Disorder and The Role of Clinicians in Addressing Them

Professor Christoph Correll discusses the complexities of bipolar disorder, shedding light on the real-world challenges in treatment, the critical role of clinicians, and the necessity of patient-centric approaches in psychiatry.

06.03.2024 Mental Health
The Heterogeneity of Bipolar Disorder: From Clinical Observations to Precision Psychiatry play_circle Video play_circle
The Heterogeneity of Bipolar Disorder: From Clinical Observations to Precision Psychiatry

Bipolar disorder is a chronic and highly debilitating mental disorder characterized by recurrent mood episodes. A major challenge is its heterogeneous clinical presentation with diverse comorbidities and symptomatology.

06.03.2024 Mental Health